FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colon cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colon cancer patients with liver metastasis.

Trial Details

NCT ID
NCT06801665
Phase
PHASE2
Sponsor
Hua Jiang
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • FMT+QL1706+Bevacizumab+XELOX
Locations (sample)
  • Changzhou, China|31.77359,119.95401

Key Eligibility Criteria

  • Histological or cytological confirmed advanced colon cancer with liver metastasis.
  • Signed written informed consent.
  • Have not received anti-tumor treatment.
  • According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →